Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 19:38:191.
doi: 10.11604/pamj.2021.38.191.24301. eCollection 2021.

Assessing the prevalence and effect of adverse drug reactions among patients receiving first line anti-tubercular medicines in the Tamale Teaching Hospital, Ghana

Anthony Amalba  1 , Amos Adapalala Bugri  2
Affiliations

Assessing the prevalence and effect of adverse drug reactions among patients receiving first line anti-tubercular medicines in the Tamale Teaching Hospital, Ghana

Anthony Amalba et al. Pan Afr Med J. .

Abstract

Introduction: tuberculosis (TB) remains a global major health problem, especially in developing countries. Although treatment regimen for TB has been highly effective, treatment-related adverse effects account for significant morbidity leading to reduced effectiveness of therapy and high default rate. This study evaluated the nature and occurrence of Adverse Drug Reactions (ADRs) in patients receiving first line antitubercular therapy (ATT) in Tamale Teaching Hospital (TTH) and its effects on adherence.

Methods: the study was a cross-sectional study for a period of six months. A total of 66 participants who were on first line antituberculotic therapy consented for the study. Data was collected using a questionnaire and analysed using SPSS version 22.0.

Results: about 77% (n=51) of the participants had experienced ADRs. Gastrointestinal symptoms were the most commonly reported symptoms of ADR (80%, n=41). Regarding adherence, over half (51.0%, n=26) said the occurrence of the Adverse Drug Reaction had affected the manner in which they take their medications. Of these, 84.6% (n=22) of the participants indicated that they skipped/missed their medications and 15.4% stopped the medication entirely. About 39.2% (n=20) reported ADRs to a healthcare practitioner and 60.8% did not. All the reported cases were managed by a health practitioner using another medication.

Conclusion: the study showed that ADRs are common among patients receiving first line ATT. Gastrointestinal tract (GIT) related ADRs were the most common. Adherence to first line antitubercular therapy is poor as a result of adverse drugs reaction.

Keywords: Adverse drug reactions; Tamale; adherence; anti-tuberculosis therapy; medication; occurrence; tuberculosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
adverse reactions experienced by patients
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Gasana M, Vandebriel G, Kabanda G, Tsiouris SJ, Justman J, Sahabo R, et al. Integrating tuberculosis and HIV care in rural Rwanda. Int J Tuberc Lung Dis. 2008 Mar;12(3) Suppl 1:39–43. - PMC - PubMed
    1. Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol. 2013 Mar;3(1):37–49. - PMC - PubMed
    1. Marais BJ, Brittle W, Painczyk K, Hesseling AC, Beyers N, Wasserman E, et al. Use of light-emitting diode fluorescence microscopy to detect acid-fast bacilli in sputum. Clin Infect Dis. 2008 Jul 15;47(2):203–7. - PubMed
    1. Zumla A, George A, Sharma V, Rt Hon Herbert N, Baroness Masham of Ilton; Oxley A, Oliver M. The WHO 2014 global tuberculosis report—further to go. Lancet Glob Health. 2015 Jan;3(1):e10–2. - PubMed
    1. Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet. 2007 Jun 16;369(9578):2042–2049. - PubMed

MeSH terms

Substances